Study 1 : G. JOST, "Expert report on LF 41": this study shows that STÉRIMAR ® (LF41) significantly reduces local symptoms such as swelling, dried mucus and hypersecretions in patients with respiratory disorders.

Study 2 : B. AZOULAY, "Use of STÉRIMAR ® in ENT hygiene": this study shows that STÉRIMAR ® aids in nose-blowing, in the drainage of the nasal fossae, and allows for perfect hygiene of the nasal mucosa.

Study 3 : J. BRUKER, "STÉRIMAR ® as a factor in nasal hygiene": this study demonstrates the improvement in clinical signs shown by patients treated with STÉRIMAR ®. These patients were suffering from rhinitis, rhinosinusitis or rhinopharyngitis. The convenience of the treatment and the absence of any side effects were also demonstrated.

Study 4 : Ph. CONTENCIN, "STÉRIMAR ® in rhinopharyngeal disinfection in children": this study highlights the effects produced by STÉRIMAR ® on children suffering from obstructive or dry rhinitis. It also demonstrates the safety and excellent compliance with the treatment.

Study 5 : A. MARSAC, "Use of STÉRIMAR ® in common rhinosinusitis": this study demonstrates the disappearance of clinical and functional symptoms in patients treated with STÉRIMAR ®. The treatment is also shown to be excellent in terms of tolerance and acceptability.

Study 6 : J. FOUGEROL, "STÉRIMAR ®, respiratory relief and allergic rhinitis in adults": this study recommends STÉRIMAR ® in order to reduce clinical and functional symptoms in allergic rhinitis. The study also demonstrates the relief provided by the treatment and the absence of side effects.

Study 7 : G. SCADDING - England, "Nasal cleansing as part of the treatment of chronic rhinosinusitis": this study demonstrates the improvement in clinical and functional symptoms in patients treated with STÉRIMAR ®. The treatment is shown to offer excellent safety, tolerance and acceptability.

Study 8 : S. MORINIÈRE, E. LESCANNE, Z. CELEBI, M.-J. PLOYET, "Use of STÉRIMAR ® Copper solution in the treatment of infectious rhinitis in children": this study supports previous publications in demonstrating that STÉRIMAR ® can be helpful in the treatment of infectious processes in children.

Study 9 : Ph. CONTENCIN, "Use of STÉRIMAR ® Cu and Mn in paediatric ENT: can STÉRIMAR ® Copper or Manganese be used in children and babies?": this study demonstrates the absence of side effects and also perfect tolerance by babies and children.

Study 10 : DSc Zivko GNJIDIC – Croatia, "Cleaning of the nasal cavities with STÉRIMAR ® Copper and STÉRIMAR ® Manganese after operating on a tumor in the pituitary fossa region (trans-sphenoid approach)": this study demonstrates that the use of STÉRIMAR ® Manganese and Copper improves the condition of nasal cavities sensitised following surgery in the pituitary fossa region.

Study 11 : Prim. M. Sc. Dr Miljenko RAOS – Croatia, "Comparison between the use of STÉRIMAR ® Manganese microdiffusion and physiological serums in patients suffering from allergic rhinitis": this study demonstrates that STÉRIMAR ® Manganese is well tolerated by all paediatric patients and also proves more effective than physiological serum on a number of symptoms.

Study 12 : A. MARSAC "Use of STÉRIMAR ® Sulphur in children". Children from 6 months to 12 years having mucous rhinitis and muco suppurating rhinitis were included. Rhinorrhea was descreased or stopped in 83% of cases. Tolerance was fine.

Study 1 : Research by PARSONS in 1996
This study demonstrates improved mucociliary clearance in the presence of hypertonic solutions. This author was the first to highlight the value of salt solutions in the treatment of rhinosinusitis. He notes that nasal cleansing has been recommended for over a century. The study was carried out in 21 healthy non-smoking volunteers aged 25-45 who were not taking any treatments. Each volunteer served as his own control. The author used a buffered hypertonic solution whose formula is given.
In most cases, the mechanism of action of the hypertonic solution helped to enhance the wave-like action of the cilia by reducing the viscosity of the mucus. The author concludes that the hypertonic solution, used to treat chronic sinusitis/rhinitis and to facilitate postoperative nasal cleansing (removal of secretions, dried mucus, etc.) clearly has the ability to increase nasal mucociliary clearance .

Study 2 : FRECHE et al. Hypertonic sea water in rhinology. Official Journal of the French ENT Society, Vol. 50 – 1998.
Frèche et al. (3) conducted a study in 80 adults with a rhinosinus disorder characterised by permanent or intermittent nasal obstruction, associated or not with runny nose, swollen sinuses, congestion, and hyperhemia of the nasal mucosa.
Patients were treated with hypertonic sea water (NaCl 23 g/l) for 2 weeks. The main endpoint was the reduction in nasal obstruction measured on a visual analog scale (VAS).
78 % of the patients were found to have a significant or total disappearance of nasal obstruction. Tolerance was excellent or good in 95 % of cases, indicating that the NaCl concentration is satisfactory.

Study 3 : SKOUPA, 2007
The efficacy of a combination of hypertonic sea water and nasal corticosteroids was studied in adults suffering from chronic or recurrent rhinosinusitis.
Group 1 only received corticosteroids while Group 2 received a combination of corticosteroids + salt water for 2 weeks, followed by salt water alone. Group 3 discontinued corticosteroids upon entering the study and used only salt water. Groups 2 and 3 were allowed to use corticosteroids as an "emergency" treatment when necessary. After 6 weeks of follow-up, all clinical scores for rhinitis had significantly improved in the groups receiving salt water as compared with group 1 (p<0.05).
Similarly, use of nasal corticosteroids, which was unchanged in the first group, significantly decreased at each visit in the other two groups. Quality of life scores also increased (p<0.05).
The authors conclude that treatment with a hypertonic sea water solution improved the condition of the nose in these patients and reduced their use of local corticosteroids.